Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 2.22% is 34% above its 5-year average of 1.65%, around the middle of its 5-year range (-24.39%–28.21%).
85.32% below its 12-month average of 15.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.28%.
RETURN ON ASSETS (ROA)
2.22%
RETURN ON ASSETS (ROA) AVG TTM
15.13%
RETURN ON ASSETS (ROA) AVG 3Y
10.21%
RETURN ON ASSETS (ROA) AVG 5Y
1.65%
RETURN ON ASSETS (ROA) AVG 10Y
4.68%
RETURN ON ASSETS (ROA) AVG 15Y
-0.47%
RETURN ON ASSETS (ROA) AVG 20Y
-20.30%
CURRENT VS TTM AVG
-85.32%
CURRENT VS 3Y AVG
-78.26%
CURRENT VS 5Y AVG
+34.41%
CURRENT VS 10Y AVG
-52.55%
CURRENT VS 15Y AVG
+569.01%
CURRENT VS 20Y AVG
+110.94%
SECTOR MEDIAN · HEALTHCARE
-29.10%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+107.63%
vs the sector median at left
MiMedx Group, Inc.
Market Cap
$665.40M
Return on Assets (ROA)
2.22%
TTM Avg
15.13%
3Y Avg
10.21%
5Y Avg
1.65%
Market Cap
$666.36M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$666.95M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$676.72M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$643.45M
Return on Assets (ROA)
-15.25%
TTM Avg
-20.29%
3Y Avg
-14.84%
5Y Avg
-12.37%
Market Cap
$692.29M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$636.48M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$635.69M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$704.02M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | $665.40M | 2.22% | 15.13% | 10.21% | 1.65% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.36M | -36.37% | -26.71% | -31.04% | -27.33% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -70.67% | -51.05% | -54.02% | -55.25% |
| Annexon, Inc. (ANNX)vs › | $676.72M | -82.36% | -56.97% | -52.21% | -45.34% |
| OmniAb, Inc. (OABI)vs › | $643.45M | -15.25% | -20.29% | -14.84% | -12.37% |
| Anteris Technologies Global Corp. (AVR)vs › | $692.29M | -38.01% | -251.96% | -211.47% | -174.45% |
| Climb Bio, Inc. (CLYM)vs › | $636.48M | -23.40% | -34.85% | -33.75% | -41.05% |
| Aura Biosciences, Inc. (AURA)vs › | $635.69M | -37.63% | -55.16% | -41.63% | -48.17% |
| Faeth Therapeutics, Inc. (FTH)vs › | $704.02M | -103.29% | -79.28% | -61.36% | -60.54% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $707.95M | -42.04% | -29.58% | -35.66% | -28.85% |
ROA
2.2%
ROE
2.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 14.18% |
| 2024-12-31 | 16.07% |
| 2023-12-31 | 28.21% |
| 2022-12-31 | -17.61% |
| 2021-12-31 | -6.55% |
| 2020-12-31 | -24.39% |
| 2019-12-31 | -15.30% |
| 2018-12-31 | -24.40% |
| 2017-12-31 | 53.38% |
| 2016-12-31 | 6.20% |
| 2015-12-31 | 21.67% |
| 2014-12-31 | 5.69% |
| 2013-12-31 | -4.85% |
| 2012-12-31 | -21.78% |
| 2011-12-31 | -37.62% |
| 2010-12-31 | -155.32% |
| 2009-12-31 | -122.98% |
| 2008-12-31 | -114.45% |
| 2007-12-31 | -21119.57% |
| 2006-12-31 | -120.83% |
